These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 26049002)
1. A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. Zeng W; Tan AC; Horrocks K; Jackson DC Vaccine; 2015 Jul; 33(30):3526-32. PubMed ID: 26049002 [TBL] [Abstract][Full Text] [Related]
2. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e. Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545 [TBL] [Abstract][Full Text] [Related]
3. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411 [TBL] [Abstract][Full Text] [Related]
5. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine. Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Liu W; Zou P; Chen YH Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608 [TBL] [Abstract][Full Text] [Related]
7. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982 [TBL] [Abstract][Full Text] [Related]
8. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Zhou C; Zhou L; Chen YH Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634 [TBL] [Abstract][Full Text] [Related]
10. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge. Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G Virol J; 2013 Jul; 10():227. PubMed ID: 23834899 [TBL] [Abstract][Full Text] [Related]
11. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice. Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418 [TBL] [Abstract][Full Text] [Related]
12. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235 [TBL] [Abstract][Full Text] [Related]
13. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216 [TBL] [Abstract][Full Text] [Related]
14. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model. Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens. Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342 [TBL] [Abstract][Full Text] [Related]
16. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge. Kaminaka K; Matsuda J; Nozaki C Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675 [TBL] [Abstract][Full Text] [Related]
17. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548 [TBL] [Abstract][Full Text] [Related]
18. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. Heinen PP; Rijsewijk FA; de Boer-Luijtze EA; Bianchi ATJ J Gen Virol; 2002 Aug; 83(Pt 8):1851-1859. PubMed ID: 12124449 [TBL] [Abstract][Full Text] [Related]